home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Amarant Pharmaceuticals (Pvt) Ltd.

SHARESHARESHARE
Amarant Pharma Pharmaceuticals is built on a solid foundation of talented people, unparalleled research and development platform, a strong clinical and commercial presence and trust of its loyal quality conscious prescribers. These factors have enabled Amarant Pharma, in just 6 years, to grow from a bold young startup to a leading pharmaceutical company in Pakistan.
SHARESHARESHARE

RELATED NEWS


ConcertAI has hired Claudio D'Ambrosio, PhD, as head of biopharma partnerships and real-world evidence Solutions. Claudio brings over 15 years of experience as a cancer researcher, commercial leader, and strategic scientific partner to the life sciences industry to help advance the goals of ConcertAI of bringing rapid innovation and precision real-world evidence oncology to the world's top global pharmaceutical companies. ConcertAI is a fast-growing company with the leading technology fo...
PRNEWSWIRE
READ MORE

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a price advantage over BMS’ rival drug. The combination of anti-PD-1 therapy Keytruda with tyrosine kinase inhibitor Inlyta (axitinib) reduced risk of death in RCC by around 47%, compared with Pfizer’s established cancer drug Sutent (sunitinib), in phase 3 KEYNOTE-426 study – announce...

READ MORE

Irish pharma firm Galen has announced the completion of its POA Pharma (POA) acquisition. The company has stated that the multi-million pound takeover will help to “significantly expand” its global reach and product portfolio in exciting new therapy areas, such as rare metabolic disease. The deal first got underway back in April 2016, when Galen signed a distribution agreement with POA, allowing the company to market and sell POA’s metabolic product portfolio in the UK and Irel...

READ MORE

The environment could be as important a battleground as the clinic in the global fight against the spread of antibiotic resistance, new research has shown. A study conducted at the University of Exeter Medical School concluded that when bacteria are exposed to very low concentrations of antibiotics, numbers of antibiotic-resistant bacteria increase just as much as at high clinical concentrations. Antimicrobial resistance (AMR) is recognized by the World Health Organization (WHO) as one of today&...
UNIVERSITY OF EXETER
READ MORE

Washington DC: Urine drug testing can be a useful tool to treat patients with opioid use disorder in a primary care setting, suggests a new study. A urine drug test, also known as a urine drug screen or a UDS, is the analysis of an individual's urine for the presence of certain illegal drugs and prescription medications. The study, which was conducted by researchers at the Boston University School of Medicine, revealed that patients are less likely to disclose drug use earlier in treatment, ...

READ MORE

ImmuPharma and Avion Pharmaceuticals have signed an exclusive licensing agreement for Lupuzor (rigerimod), ImmuPharma’s lead compound, a peptide therapeutic and a first-in class autophagy immunomodulator for systemic lupus erythematosus (SLE or lupus). Under the terms of the deal, the companies will co-develop Lupuzor to allow registration for marketing in the US, Europe and elsewhere, and Avion will commercialise the drug exclusively for the US. ImmuPharma will also retain all the rights ...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...